The long-term objective for the new Clinical Immunobiology Correlative Studies Laboratory (CICSL) is to develop into a comprehensive, cutting-edge correlative studies laboratory to support clinical trial and translational research efforts sponsored primarily by Cancer Center investigators at City of Hope. Long-term specific aims include i) continued development and implementation of novel immunological platforms and assays, identified either from external sources or internally, that will support, in a significant way, ongoing and future clinical trials;ii) continued expansion of user base to reflect support, in magnitude and diversity, of the majority of correlative assay needs of Cancer Center investigators;iii) continued evolution and implemention of laboratory operating policies and infrastructure to adhere to GLP practices and ultimately lead to CLIA certification of the laboratory. The principle objective of the laboratory is to develop and implement quantitative methods to evaluate the effect of novel therapies on a patient's immune system, and correlate those effects with treatment outcome to guide the rational development of efficacious therapeutic regimens. The research design and methods for the laboratory are to identify technology platforms that would be most useful and appropriate to evaluate the effect of therapeutic modalities on patients, and to develop assays based on those platforms that could be used to evaluate clinical trials sponsored by Cancer Center investigators. To that end, the laboratory has expertise and infrastructure to develop molecular, flowbased and cell-based assays. The laboratory operates under GLP guidelines, a fact that supports a high standard of operations. During the most recent 10-month reporting period, the CICSL shared resource was used by 13 Cancer Center members from all 5 programs. Peer-reviewed usage represented 79% of total usage. Annual budget for this core is $603,900, of which 47% is institutional funding, 28% is user fees, 15% is from other sources, and 10% ($60,100) is requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-27
Application #
8182271
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
27
Fiscal Year
2010
Total Cost
$83,530
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165
Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :
Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Oh, Eunjin; Ahn, Miwon; Afelik, Solomon et al. (2018) Syntaxin 4 Expression in Pancreatic ?-Cells Promotes Islet Function and Protects Functional ?-Cell Mass. Diabetes 67:2626-2639

Showing the most recent 10 out of 1396 publications